Physicians' Academy for Cardiovascular Education

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD

Improving outcomes for patients following an admission with ADHF

15' education - July 7, 2020 - Prof. Mark Petrie, MD and Klaus Witte, MD

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

Tools to detect FH

10' education - June 23, 2020 - Rens Reeskamp, MD

DKD and CV risk: What is the potential of targeting GLP-1?

10' education - June 16, 2020 - Prof. Erik Stroes, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Mark Cooper, MD

Familial hypercholesterolemia in children and adolescents

10' education - June 2, 2020 - Bert Wiegman, MD, PhD

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. J. Wouter Jukema, MD - Leiden, The Netherlands

Reduction of revascularization with icosapent ethyl in patients with hypertriglyceridemia

3' education - May 25, 2020 - Benjamin Peterson, MD

Increase in out-of-hospital cardiac arrest during the COVID-19 outbreak in Lombardy, Italy

3' education - May 8, 2020 - Enrico Baldi, MD

Venous thromboembolism in COVID-19 patients

5' education - May 6, 2020 - Prof. Saskia Middeldorp

Obesity as a risk factor for severity of COVID-19: multiple potential mechanisms

5' education - May 1, 2020 - Prof. Naveed Sattar, MD

COVID-19 associated thrombotic complications

5' education - Apr. 22, 2020 - Erik Klok, MD, PhD
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
Lecture (panel discussion) 3 out of 3

COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?

10' education - Apr. 17, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

HFA publishes a position paper on SGLT2i in heart failure

News - July 15, 2020

The Heart Failure Association of the ESC has recently published a position paper on SGLT2i therapy in heart failure, beyond glycemic control.

SGLT2i reduces left ventricular mass in T2DM patients with LVH

Literature - July 14, 2020 - Brown AJM, et al. - Eur Heart J 2020

1-year treatment with dapagliflozin reduced left ventricular mass (LVM) compared to placebo in T2DM patient with left ventricular hypertrophy, suggesting that dapagliflozin initiates cardiac reverse remodeling.

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD
Prof. Wanner presents a case of a patient with CKD who develops diabetes. He discusses what the optimal treatment strategy for such a patient is and how new treatments have resulted in a paradigm shift in nephrology.

Prof. Wanner presents a case of a CKD patient who has developed diabetes. He discusses what the optimal treatment strategy for such a patient is and how new treatments have resulted in a paradigm shift in nephrology.

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD
Nick Nurmohamed explains what Lp(a) is and how correction of LDL-c for Lp(a) reduces genetic testing for FH.

Nick Nurmohamed explains what Lp(a) is and how correction of LDL-c for Lp(a) reduces genetic testing for FH.

GLP-1RA might reduce cognitive impairment in T2DM

Literature - July 13, 2020 - Cukierman-Yaffe T, et al. - Lancet Neurol 2020

Treatment with the GLP-1RA dulaglutide for a median of 5.4 years resulted in a reduction of cognitive impairment compared to placebo in T2DM patients ≥50 years, in an exploratory analysis of REWIND.

A scientific statement of AHA on amyloidosis

News - July 13, 2020

The American Heart Association has published a scientific statement covering diagnosis and management of transthyretin amyloid cardiomyopathy (ATTR-CM).

Larger proportion of incident unrecognized MI in women

Literature - July 13, 2020 - Van der Ende MY, et al. - J Am Heart Assoc. 2020

Using data of the Lifelines Cohort Study including a contemporary adult population, this study showed that 30% of MIs in women are unrecognized vs. 16% in men.

Higher frequency of coronary atherosclerotic plaques in patients with genetically confirmed FH

Literature - July 7, 2020 - Pang J et al., - Atherosclerosis. 2020.

Among asymptomatic phenotypic FH patients, patients with a genetically confirmed FH diagnosis had a higher frequency and severity of coronary atherosclerotic plaques, compared to those without a FH-causing mutation.

Extended-duration DOAC reduces fatal and major thromboembolic events in medically ill patients

Literature - July 7, 2020 - Spyropoulos AC et al., - J Am Coll Cardiol. 2020.

Treatment with 10 mg rivaroxaban reduces fatal and major thromboembolic events without significantly increasing major bleeding in medically ill patients after discharge, compared to placebo.

Improving outcomes for patients following an admission with ADHF

15' education - July 7, 2020 - Prof. Mark Petrie, MD and Klaus Witte, MD

Using a case of a heart failure (HF) patient who was admitted to the hospital with acute decompensated HF (ADHF), two specialists discuss what the optimal treatment strategy in hospitalized patients should be during time of admission.

Risk of ASCVD gradually increases with increasing SBP levels starting from 90 mmHg

Literature - July 6, 2020 - Whelton SP et al. - JAMA Cardiol. 2020.

Presence of coronary artery calcium and risk of incident ASCVD events increased with increasing SBP levels in individuals with a SBP between 90 and 129 mmHg and no other traditional ASCVD risk factors.

LVEF deterioration into midrange levels increases risk of adverse outcomes in HFmrEF

Literature - July 2, 2020 - Brann A et al., - JAMA Cardiol. 2020.

Patients whose LVEF deteriorated from normal to midrange levels had a significantly higher risk of adverse clinical outcomes compared to those whose LVEF had improved from lower values.